Madrigal Pharmaceuticals
MDGL
111 hedge funds and large institutions have $831M invested in Madrigal Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 47 increasing their positions, 27 reducing their positions, and 17 closing their positions.
74% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 27
0.17% more ownership
Funds ownership: 62.32% → 62.49% (+0.17%)
4% less funds holding
Funds holding: 116 → 111 (-5)
17% less capital invested
Capital invested by funds: $1.01B → $831M (-$176M)
24% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 17
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
51% less call options, than puts
Call options by funds: $6.99M | Put options by funds: $14.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$71.3M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.67M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$2.45M |
| 4 |
SG Americas Securities
New York
|
+$2.23M |
| 5 |
Morgan Stanley
New York
|
+$1.92M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$28.1M |
| 2 |
State Street
Boston,
Massachusetts
|
-$10.8M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$8.29M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$7.01M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$4.36M |
MDGL Hedge Fund Activity: Q3 2019 in Review
111 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Madrigal Pharmaceuticals (MDGL) for Q3 2019, worth a combined $831M — down 17% from $1.01B a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of MDGL and 13 opened new positions — a net loss of 4 holders — while 27 trimmed existing stakes and 47 added.
The largest buyer was Wellington Management Group, adding an estimated $71.3M. The largest seller was Armistice Capital, cutting an estimated $28.1M.
- 111 institutional investors held Madrigal Pharmaceuticals (MDGL) as of Q3 2019, down from 116 in Q2 2019.
- Funds reported $831M of Madrigal Pharmaceuticals stock for Q3 2019, down 17% quarter-over-quarter.
- 13 funds opened new Madrigal Pharmaceuticals positions in Q3 2019 and 17 closed out, a net change of -4 holders.
- The largest Madrigal Pharmaceuticals buyer in Q3 2019 was Wellington Management Group, an estimated $71.3M added.
- The largest Madrigal Pharmaceuticals seller in Q3 2019 was Armistice Capital, an estimated $28.1M sold.
Based on aggregated 13F filings for Q3 2019.